SWX:PPGNLife Sciences
Does PolyPeptide’s 2025 Margin Outlook From Metabolic Therapies Shift The Bull Case For PolyPeptide Group (SWX:PPGN)?
PolyPeptide Group AG recently reported preliminary 2025 figures pointing to about €389 million in revenue and an EBITDA margin of 11.0%–12.0%, supported by demand for metabolic therapeutics and ongoing capital spending.
This early look at revenue and profitability offers investors an insight into how exposure to metabolic therapies may be reshaping PolyPeptide’s business mix ahead of its full audited 2025 results on 12 March 2026.
Next, we’ll explore how this improved EBITDA margin guidance...